Posted by Michael Wonder on 20 Sep 2023
European Commission approves Pfizer’s Litfulo for adolescents and adults with severe alopecia areata
19 September 2023 - Pfizer today announced that the European Commission has granted marketing authorisation for Litfulo (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe alopecia areata.
Litfulo, a once daily oral capsule, is the first medicine authorised by the European Commission to treat individuals as young as 12 years of age with severe alopecia areata.
